From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO

Your direct line with Madrid

The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.

Stay tuned, and get ready for an exciting and informative journey!

With the educational support of:

Presidential highlights

Prof Herbert Loong: LIBRETTO 431

Prof Herbert Loong, representing the Chinese University of Hong Kong, presented a late-breaking abstract at ESMO 2023, the LIBRETTO 431 trial. This trial investigates the use of selpercatinib, a selective

See video »

Prof Nicolas Girard: PAPILLON

At ESMO 2023, the results of the Papillon study, a phase 3 trial comparing amivantamab plus chemotherapy to chemotherapy alone in first-line treatment for EGFR exon 20 insertion-mutated non-transcendent (Ex20ins)

See video »

Daily highlights in lung cancer

Daily highlight in non-metastatic NSCLC

Dr Mariana Brandao, a medical oncologist at the Clinic of Thoracic Oncology at the Institute Jules Bordet in Brussels, provided insights into various mini-oral presentations focusing on non-metastatic NSCLC.

In the

See video »

Daily highlight in lung cancer

The FLAURA2 trial, where initial data unveiled at the World Lung Conference showed that integrating chemotherapy into the standard care for EGFR-mutated patients significantly enhanced progression-free survival (PFS) by approximately

See video »

Daily highlight in metastatic NSCLC

Professor Els Wauters, a respiratory oncologist at the University Hospital Leuven, discusses the proffered paper sessions of ESMO2023 in Madrid.
In the phase 3 SAPPHIRE trial, researchers investigated the impact

See video »

In-depth stories about lung cancer

The PACIFIC-06 Study

At ESMO 2023, exciting data on lung cancer were presented, including insights from the PACIFIC-06 study. The study was presented by Prof Marina Garassino, from the University of Chicago.

See video »

The FINN study

Prof Lore Decoster, a medical oncologist at UZ-Brussels, presented an analysis of the FINN study, a real-world prospective investigation into the combination of ipilimumab and nivolumab, often referred to as

See video »

The AEGEAN study – The promise of ctDNA

Prof Martin Reck from the Lung Clinic Grosshansdorf presented game-changing insights. AEGEAN is the latest addition to perioperative chemoimmunotherapy trials for resectable NSCLC, akin to KEYNOTE 671, exploring the role

See video »

The KRYSTAL-7 study

The KRYSTAL-7 study, presented at the ESMO Congress 2023, holds substantial promise for advancing the treatment of advanced NSCLC. This phase 2 trial focused on assessing a combination treatment involving

See video »

The KEYNOTE – 671 Study

In this conversation at the ESMO Congress 2023 in Madrid, Mariana Brandão, a medical oncologist at the Jules Bordet Institute, and Lore Decoster, medical oncologist at the University Hospital Brussels,

See video »

The CheckMate- 816 Study

Prof Nicolas Girard, Director of Medical Oncology at Institut Curie in Paris, presented an overview of the CheckMate 816 trial’s findings during the ESMO 2023 meeting. This randomised study focused

See video »

Lung cancer poster selection

With the educational support of:

Z1. Researchpark 30, 1731 Zellik, Belgium
Website created by MediMix © 2023 - Privacy Policy